{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T23:34:15Z","timestamp":1781048055745,"version":"3.54.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CURR MED SCI"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1007\/s11596-019-2024-4","type":"journal-article","created":{"date-parts":[[2019,4,23]],"date-time":"2019-04-23T14:04:01Z","timestamp":1556028241000},"page":"228-236","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["HDAC-selective Inhibitor Cay10603 Has Single Anti-tumour Effect in Burkitt\u2019s Lymphoma Cells by Impeding the Cell Cycle"],"prefix":"10.1007","volume":"39","author":[{"given":"Xiu-juan","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-jie","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Di","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-ning","family":"Miao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,8,5]]},"reference":[{"issue":"19","key":"2024_CR1","doi-asserted-by":"publisher","first-page":"2913","DOI":"10.1182\/blood-2014-06-538504","volume":"124","author":"C Jacobson","year":"2014","unstructured":"Jacobson C, LaCasce A. How I treat Burkitt lymphoma in adults. Blood, 2014, 124(19):2913\u201320.","journal-title":"Blood"},{"issue":"4","key":"2024_CR2","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1200\/JCO.2010.33.3369","volume":"30","author":"MS Cairo","year":"2012","unstructured":"Cairo MS, Sposto R, Gerrard M, et al. Advanced stage, increased lactate dehydrogenase, and primary site, but not adolescent age (>\/= 15 years), are associated with an increased risk of treatment failure in children and adolescents with mature B-cell non-Hodgkin\u2019s lymphoma: results of the FAB LMB 96 study. J Clin Oncol, 2012,30(4):387\u2013393","journal-title":"J Clin Oncol"},{"issue":"6","key":"2024_CR3","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1111\/j.1365-2141.2011.09024.x","volume":"156","author":"RR Miles","year":"2012","unstructured":"Miles RR, Arnold S, Cairo MS. Risk factors and treatment of childhood and adolescent Burkitt lymphoma\/leukaemia. Br J Haematol, 2012,156(6):730\u2013743","journal-title":"Br J Haematol"},{"issue":"9","key":"2024_CR4","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/nrd4360","volume":"13","author":"KJ Falkenberg","year":"2014","unstructured":"Falkenberg KJ, Johnstone RW. Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders. Nat Rev Drug Discov, 2014,13(9):673\u2013691","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"2024_CR5","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1172\/JCI69738","volume":"124","author":"AC West","year":"2014","unstructured":"West AC, Johnstone RW. New and emerging HDAC inhibitors for cancer treatment. J Clin Invest, 2014,124(1):30\u201339","journal-title":"J Clin Invest"},{"issue":"11","key":"2024_CR6","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1111\/cas.13062","volume":"107","author":"Y Imai","year":"2016","unstructured":"Imai Y, Maru Y, Tanaka J. Action mechanisms of histone deacetylase inhibitors in the treatment of hematological malignancies. Cancer Sci, 2016,107(11):1543\u20131549","journal-title":"Cancer Sci"},{"issue":"5","key":"2024_CR7","volume":"18","year":"2017","unstructured":"Stephan D, Weiher H, Schmidt-Wolf IGH. CIK Cells and HDAC Inhibitors in Multiple Myeloma. Int J Mol Sci, 2017,18(5)","journal-title":"Int J Mol Sci"},{"issue":"2","key":"2024_CR8","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.yexcr.2018.07.017","volume":"370","author":"OA Bamodu","year":"2018","unstructured":"Bamodu OA, Kuo KT, Yuan LP, et al. HDAC inhibitor suppresses proliferation and tumorigenicity of drug-resistant chronic myeloid leukemia stem cells through regulation of hsa-miR-196a targeting BCR\/ABL1. Exp Cell Res, 2018,370(2):519\u2013530","journal-title":"Exp Cell Res"},{"issue":"28","key":"2024_CR9","doi-asserted-by":"publisher","first-page":"3839","DOI":"10.1038\/s41388-018-0234-z","volume":"37","author":"M Pinazza","year":"2018","unstructured":"Pinazza M, Ghisi M, Minuzzo S, et al. Histone deacetylase 6 controls Notch3 trafficking and degradation in T-cell acute lymphoblastic leukemia cells. Oncogene, 2018,37(28):3839\u20133851","journal-title":"Oncogene"},{"issue":"6","key":"2024_CR10","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1038\/bjc.2016.36","volume":"114","author":"E Ceccacci","year":"2016","unstructured":"Ceccacci E, Minucci S. Inhibition of histone deacetylases in cancer therapy: lessons from leukaemia. Br J Cancer, 2016,114(6):605\u2013611","journal-title":"Br J Cancer"},{"issue":"8","key":"2024_CR11","volume":"19","year":"2018","unstructured":"Cosenza M, Pozzi S. The Therapeutic Strategy of HDAC6 Inhibitors in Lymphoproliferative Disease. Int J Mol Sci, 2018,19(8)","journal-title":"Int J Mol Sci"},{"issue":"6","key":"2024_CR12","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1111\/j.1365-2559.2009.03290.x","volume":"54","author":"L Marquard","year":"2009","unstructured":"Marquard L, Poulsen CB, Gjerdrum LM, et al. Histone deacetylase 1, 2, 6 and acetylated histone H4 in B- and T-cell lymphomas. Histopathology, 2009,54(6):688\u2013698","journal-title":"Histopathology"},{"key":"2024_CR13","doi-asserted-by":"publisher","first-page":"e610","DOI":"10.1038\/cddis.2013.127","volume":"4","author":"T Ozaki","year":"2013","unstructured":"Ozaki T, Wu D, Sugimoto H, et al. Runt-related transcription factor 2 (RUNX2) inhibits p53-dependent apoptosis through the collaboration with HDAC6 in response to DNA damage. Cell Death Dis, 2013,4:e610","journal-title":"Cell Death Dis"},{"issue":"1","key":"2024_CR14","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s13045-018-0654-9","volume":"11","author":"T Li","year":"2018","unstructured":"Li T, Zhang C, Hassan S, et al. Histone deacetylase 6 in cancer. J Hematol Oncol, 2018,11(1):111","journal-title":"J Hematol Oncol"},{"issue":"2","key":"2024_CR15","doi-asserted-by":"publisher","first-page":"169","DOI":"10.3233\/CBM-160298","volume":"19","author":"Z Zhang","year":"2017","unstructured":"Zhang Z, Cao Y, Zhao W, et al. HDAC6 serves as a biomarker for the prognosis of patients with renal cell carcinoma. Cancer Biomark, 2017,19(2):169\u2013175","journal-title":"Cancer Biomark"},{"issue":"1","key":"2024_CR16","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.canlet.2016.06.001","volume":"379","author":"Z Wang","year":"2016","unstructured":"Wang Z, Hu P, Tang F, et al. HDAC6 promotes cell proliferation and confers resistance to temozolomide in glioblastoma. Cancer Lett, 2016,379(1):134\u2013142","journal-title":"Cancer Lett"},{"issue":"15","key":"2024_CR17","doi-asserted-by":"publisher","first-page":"4370","DOI":"10.1021\/jm8002894","volume":"51","author":"AP Kozikowski","year":"2008","unstructured":"Kozikowski AP, Tapadar S, Luchini DN, et al. Use of the nitrile oxide cycloaddition (NOC) reaction for molecular probe generation: a new class of enzyme selective histone deacetylase inhibitors (HDACIs) showing picomolar activity at HDAC6. J Med Chem, 2008,51(15):4370\u20134373","journal-title":"J Med Chem"},{"issue":"1","key":"2024_CR18","doi-asserted-by":"publisher","first-page":"589","DOI":"10.3892\/or.2016.4811","volume":"36","author":"Z Wang","year":"2016","unstructured":"Wang Z, Tang F, Hu P, et al. HDAC6 promotes cell proliferation and confers resistance to gefitinib in lung adenocarcinoma. Oncol Rep, 2016,36(1):589\u2013597","journal-title":"Oncol Rep"},{"issue":"10","key":"2024_CR19","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1016\/S1470-2045(17)30578-8","volume":"18","author":"MA Dimopoulos","year":"2017","unstructured":"Dimopoulos MA, Goldschmidt H, Niesvizky R, et al. Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial. Lancet Oncol, 2017,18(10):1327\u20131337","journal-title":"Lancet Oncol"},{"issue":"1","key":"2024_CR20","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s41408-018-0154-8","volume":"9","author":"JL Kaufman","year":"2019","unstructured":"Kaufman JL, Mina R, Jakubowiak AJ, et al. Combining carfilzomib and panobinostat to treat relapsed\/refractory multiple myeloma: results of a Multiple Myeloma Research Consortium Phase I Study. Blood Cancer J, 2019,9(1):3","journal-title":"Blood Cancer J"},{"issue":"4","key":"2024_CR21","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1038\/emboj.2011.466","volume":"31","author":"V Lafarga","year":"2012","unstructured":"Lafarga V, Aymerich I, Tapia O, et al. A novel GRK2\/HDAC6 interaction modulates cell spreading and motility. EMBO J, 2012,31(4):856\u2013869","journal-title":"EMBO J"},{"issue":"3","key":"2024_CR22","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1083\/jcb.201403039","volume":"206","author":"NO Deakin","year":"2014","unstructured":"Deakin NO, Turner CE. Paxillin inhibits HDAC6 to regulate microtubule acetylation, Golgi structure, and polarized migration. J Cell Biol, 2014,206(3):395\u2013413","journal-title":"J Cell Biol"},{"issue":"3","key":"2024_CR23","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1111\/febs.12079","volume":"280","author":"Y Li","year":"2013","unstructured":"Li Y, Shin D, Kwon SH. Histone deacetylase 6 plays a role as a distinct regulator of diverse cellular processes. FEBS J, 2013,280(3):775\u2013793","journal-title":"FEBS J"},{"key":"2024_CR24","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.canlet.2017.01.033","volume":"391","author":"HW Ryu","year":"2017","unstructured":"Ryu HW, Shin DH, Lee DH, et al. HDAC6 deacetylates p53 at lysines 381\/382 and differentially coordinates p53-induced apoptosis. Cancer Lett, 2017,391:162\u2013171","journal-title":"Cancer Lett"},{"issue":"6","key":"2024_CR25","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1007\/s10495-017-1364-4","volume":"22","author":"M Cosenza","year":"2017","unstructured":"Cosenza M, Civallero M, Marcheselli L, et al. Ricolinostat, a selective HDAC6 inhibitor, shows anti-lymphoma cell activity alone and in combination with bendamustine. Apoptosis, 2017,22(6):827\u2013840","journal-title":"Apoptosis"},{"issue":"11","key":"2024_CR26","doi-asserted-by":"publisher","first-page":"e537","DOI":"10.3324\/haematol.2018.189241","volume":"103","author":"M Perez-Salvia","year":"2018","unstructured":"Perez-Salvia M, Aldaba E, Vara Y, et al. In vitro and in vivo activity of a new small-molecule inhibitor of HDAC6 in mantle cell lymphoma. Haematologica, 2018,103(11):e537\u2013e540","journal-title":"Haematologica"},{"issue":"6","key":"2024_CR27","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.semcancer.2009.07.004","volume":"19","author":"M Rowe","year":"2009","unstructured":"Rowe M, Kelly GL, Bell AI, et al. Burkitt\u2019s lymphoma: the Rosetta Stone deciphering Epstein-Barr virus biology. Semin Cancer Biol, 2009,19(6):377\u2013388","journal-title":"Semin Cancer Biol"},{"issue":"6","key":"2024_CR28","doi-asserted-by":"publisher","first-page":"e1000492","DOI":"10.1371\/journal.ppat.1000492","volume":"5","author":"K Paschos","year":"2009","unstructured":"Paschos K, Smith P, Anderton E, et al. Epstein-barr virus latency in B cells leads to epigenetic repression and CpG methylation of the tumour suppressor gene Bim. PLoS Pathog, 2009,5(6):e1000492","journal-title":"PLoS Pathog"},{"issue":"2","key":"2024_CR29","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1080\/10428190310001595713","volume":"45","author":"JP Doucet","year":"2004","unstructured":"Doucet JP, Hussain A, Al-Rasheed M, et al. Differences in the expression of apoptotic proteins in Burkitt\u2019s lymphoma cell lines: potential models for screening apoptosis-inducing agents. Leuk Lymphoma, 2004,45(2):357\u2013362","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"2024_CR30","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1182\/blood-2005-01-0168","volume":"106","author":"C Bellan","year":"2005","unstructured":"Bellan C, Lazzi S, Hummel M, et al. Immunoglobulin gene analysis reveals 2 distinct cells of origin for EBV-positive and EBV-negative Burkitt lymphomas. Blood, 2005,106(3):1031\u20131036","journal-title":"Blood"},{"issue":"2","key":"2024_CR31","volume":"4","year":"2014","unstructured":"Schmitz R, Ceribelli M, Pittaluga S, et al. Oncogenic mechanisms in Burkitt lymphoma. Cold Spring Harb Perspect Med, 2014,4(2)","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"2","key":"2024_CR32","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.pharmthera.2013.01.011","volume":"138","author":"S Diaz-Moralli","year":"2013","unstructured":"Diaz-Moralli S, Tarrado-Castellarnau M, Miranda A, et al. Targeting cell cycle regulation in cancer therapy. Pharmacol Ther, 2013,138(2):255\u2013271","journal-title":"Pharmacol Ther"},{"issue":"15","key":"2024_CR33","doi-asserted-by":"publisher","first-page":"3079","DOI":"10.1242\/dev.091744","volume":"140","author":"S Lim","year":"2013","unstructured":"Lim S, Kaldis P. Cdks, cyclins and CKIs: roles beyond cell cycle regulation. Development, 2013,140(15):3079\u20133093","journal-title":"Development"},{"issue":"1","key":"2024_CR34","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/emboj.2009.317","volume":"29","author":"SA Wickstrom","year":"2010","unstructured":"Wickstrom SA, Masoumi KC, Khochbin S, et al. CYLD negatively regulates cell-cycle progression by inactivating HDAC6 and increasing the levels of acetylated tubulin. EMBO J, 2010,29(1):131\u2013144","journal-title":"EMBO J"},{"key":"2024_CR35","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.phrs.2018.11.035","volume":"139","author":"R Roskoski Jr.","year":"2018","unstructured":"Roskoski R, Jr. Cyclin-dependent protein serine\/threonine kinase inhibitors as anticancer drugs. Pharmacol Res, 2018,139:471\u2013488","journal-title":"Pharmacol Res"},{"issue":"5","key":"2024_CR36","doi-asserted-by":"publisher","first-page":"8000","DOI":"10.3390\/molecules20058000","volume":"20","author":"JT Pai","year":"2015","unstructured":"Pai JT, Hsu CY, Hua KT, et al. NBM-T-BBX-OS01, Semisynthesized from Osthole, Induced G1 Growth Arrest through HDAC6 Inhibition in Lung Cancer Cells. Molecules, 2015,20(5):8000\u20138019","journal-title":"Molecules"},{"key":"2024_CR37","volume-title":"Free Radic Biol Med","author":"R Kang","year":"2018","unstructured":"Kang R, Kroemer G, Tang D. The Tumor Suppressor Protein p53 and the Ferroptosis Network. Free Radic Biol Med, 2018"},{"issue":"12","key":"2024_CR38","doi-asserted-by":"publisher","first-page":"5413","DOI":"10.1073\/pnas.88.12.5413","volume":"88","author":"G Gaidano","year":"1991","unstructured":"Gaidano G, Ballerini P, Gong JZ, et al. p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia. Proc Natl Acad Sci USA, 1991,88(12):5413\u20135417","journal-title":"Proc Natl Acad Sci USA"},{"issue":"11","key":"2024_CR39","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1016\/j.molmed.2010.09.002","volume":"16","author":"C Dai","year":"2010","unstructured":"Dai C, Gu W. p53 post-translational modification: deregulated in tumorigenesis. Trends Mol Med, 2010,16(11):528\u2013536.","journal-title":"Trends Mol Med"},{"issue":"12","key":"2024_CR40","doi-asserted-by":"publisher","first-page":"2905","DOI":"10.1080\/10428194.2017.1317091","volume":"58","author":"SA Dyshlovoy","year":"2017","unstructured":"Dyshlovoy SA, Rast S, Hauschild J, et al. Frondoside A induces AIF-associated caspase-independent apoptosis in Burkitt lymphoma cells. Leuk Lymphoma, 2017,58 (12):2905\u20132915","journal-title":"Leuk Lymphoma"},{"issue":"12","key":"2024_CR41","volume":"19","year":"2018","unstructured":"Mrakovcic M, Bohner L, Hanisch M, et al. Epigenetic Targeting of Autophagy via HDAC Inhibition in Tumor Cells: Role of p53. Int J Mol Sci, 2018,19(12)","journal-title":"Int J Mol Sci"}],"container-title":["Current Medical Science"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11596-019-2024-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11596-019-2024-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11596-019-2024-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,17]],"date-time":"2024-07-17T05:27:06Z","timestamp":1721194026000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11596-019-2024-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":41,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["2024"],"URL":"https:\/\/doi.org\/10.1007\/s11596-019-2024-4","relation":{},"ISSN":["2096-5230","2523-899X"],"issn-type":[{"value":"2096-5230","type":"print"},{"value":"2523-899X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"26 July 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}